NT-proBNP versus echocardiographic Markers as Predictors of cardiovascular Events in Patients with CKD G 2-4

被引：0
|
作者：
Untersteller, K. [1 ]
Rogacev, K. [2 ]
Seiler, S. [1 ]
Fliser, D. [1 ]
Heine, G. [1 ]
机构：
[1] Univ Klinikum Saarlandes, Klin Innere Med Nieren & Hochdruckkrankheiten 4, Homburg, Germany
[2] Univ Klinikum Saarlandes, Klin Innere Med Kardiol Angiol & Internist Intens, Homburg, Germany
来源：
INTERNIST | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FV10
引用
收藏
页码：13 / 14
页数：2
相关论文
共 50 条
  • [21] Rationale for the testingof cardiovascular risk in patients with COX-2 inhibitors with the biomarker NT-proBNP
    Giannitsis, E
    CLINICAL LABORATORY, 2005, 51 (1-2) : 73 - 83
  • [22] Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without cardiovascular disease
    Magnusson, M
    Melander, O
    Israelsson, B
    Grubb, A
    Groop, L
    Jovinge, S
    DIABETES CARE, 2004, 27 (08) : 1929 - 1935
  • [23] NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients
    Henrik Reinhard
    Peter R Hansen
    Niels Wiinberg
    Andreas Kjær
    Claus L Petersen
    Kaj Winther
    Hans-Henrik Parving
    Peter Rossing
    Peter K Jacobsen
    Cardiovascular Diabetology, 11
  • [24] NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients
    Reinhard, Henrik
    Hansen, Peter R.
    Wiinberg, Niels
    Kjaer, Andreas
    Petersen, Claus L.
    Winther, Kaj
    Parving, Hans-Henrik
    Rossing, Peter
    Jacobsen, Peter K.
    CARDIOVASCULAR DIABETOLOGY, 2012, 11
  • [25] Echocardiographic Findings and NT-proBNP Level in Type-2 Diabetic Patients With and Without Ischemic Heart Disease
    Castano Rodriguez, Sara
    Coma-Canella, Isabel
    Lopez Salazar, Begona
    Barba Cosials, Joaquin
    REVISTA ESPANOLA DE CARDIOLOGIA, 2009, 62 (10): : 1184 - 1188
  • [26] Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without known cardiovascular disease
    Magnusson, M
    Meander, O
    Israelsson, B
    Grubb, A
    Groop, L
    Jovinge, S
    CIRCULATION, 2003, 108 (17) : 749 - 749
  • [27] Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP
    Giannitsis, E
    CLINICAL LABORATORY, 2005, 51 (1-2) : 63 - 72
  • [28] Body mass index modifies the major adverse cardiovascular and cerebral events risk of NT-proBNP in patients with acute coronary syndrome
    He, Xiaoquan
    Fang, Xiaojing
    Wang, Jiali
    Zhao, Shumei
    Ding, Xiaosong
    Chen, Hui
    DIABETOLOGY & METABOLIC SYNDROME, 2025, 17 (01):
  • [29] NT-PROBNP AND HS-CRP BUT NOT CYSTATIN C PREDICTS CARDIOVASCULAR EVENTS IN PATIENTS WITH PAD INDEPENDENTLY OF AMBULATORY PULSE PRESSURE
    Arpegard, J.
    Skoglund, P. H.
    Ostergren, J.
    Svensson, P.
    CARDIOLOGY, 2013, 126 : 128 - 128
  • [30] Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure
    Koc, Mevluet
    Bozkurt, Abdi
    Sahin, Durmus Yidiray
    Unal, Ilker
    Acarturk, Esmeray
    CARDIOLOGY JOURNAL, 2009, 16 (01) : 43 - 51
12345